||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


Novartis successfully launches USD 5 billion bond issue

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------




Basel, February 5, 2009 - Novartis announced today the successful
launch of a major bond market transaction, issuing a two-tranche bond
with a total size of USD 5 billion that has been registered in the
US.

The transaction consists of the following tranches:

* USD 2 billion of a 5-year bond with a coupon of 4.125% (issued by
the Group's US entity, Novartis Capital Corp.)

* USD 3 billion of a 10-year bond with a coupon of 5.125% (issued
by the Group's Bermuda unit, Novartis Securities Investment Ltd.)

These bonds are registered with the U.S. Securities and Exchange
Commission as part of an automatic shelf registration statement filed
by Novartis in 2008. Both tranches are unconditionally guaranteed by
Novartis AG, which is incorporated in Switzerland and is the ultimate
parent company of the issuing entities.

This transaction further enhances the financial flexibility of
Novartis through this access to new sources of funding. Proceeds will
be used for general corporate purposes.

Novartis AG is rated Aa2 (stable outlook) by Moody's, AA- (stable
outlook) by Standard & Poor's and AA (stable outlook) by Fitch. JP
Morgan, Bank of America, Citi and Goldman Sachs were joint
book-runners.

A copy of the prospectus relating to this offering can be obtained on
the EDGAR website (www.sec.gov/edgar.shtml) operated by the SEC or by
contacting the underwriters through J.P. Morgan Securities Inc.
(+1-212-834-4533).

Disclaimer
This release contains certain forward-looking statements relating to
the Group's business, which can be identified by terminology such as
"will," or similar expressions, or by express or implied discussions
regarding the potential value of the bonds described in this release,
the Novartis Group's ability to repay all or any part of the bonds,
or potential future sales or earnings of the Novartis Group; or by
discussions of strategy, plans, expectations or intentions. You
should not place undue reliance on these statements. Such
forward-looking statements reflect the current views of the Group
regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no
guarantee that the bonds will have any particular value or can be
sold or re-sold for any particular value. Nor can there be any
guarantee that the Novartis Group will be able repay all or any part
of the bonds. Neither can there be any guarantee that the Novartis
Group, or any of its divisions or business units, will achieve any
particular financial results. In particular, management's
expectations could be affected by, among other things, whether or not
a market develops for the bonds; whether or not we issue additional
secured or unsecured debt in the future; whether we decide to redeem
the notes; uncertainties involved in the development of new
pharmaceutical products; unexpected clinical trial results, including
additional analysis of existing clinical data or unexpected new
clinical data; unexpected regulatory actions or delays with respect
to our regulated products, or government regulation generally; the
Group's ability to obtain or maintain patent or other proprietary
intellectual property protection, including the uncertainties
involved in the US litigation process; competition in general;
government, industry, and general public pricing and other political
pressures; the impact that the foregoing factors could have on the
values attributed to the Group's assets and liabilities as recorded
in the Group's consolidated balance sheet; and other risks and
factors referred to in the Prospectus and Prospectus Supplement for
the bonds, and in Novartis AG's current Form 20-F on file with the US
Securities and Exchange Commission. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those described
herein as anticipated, believed, estimated or expected. Novartis is
providing the information in these materials as of this date and does
not undertake any obligation to update any forward-looking statements
as a result of new information, future events or otherwise.

About Novartis
Novartis AG provides healthcare solutions that address the evolving
needs of patients and societies. Focused solely on healthcare,
Novartis offers a diversified portfolio to best meet these needs:
innovative medicines, preventive vaccines, diagnostic tools,
cost-saving generic pharmaceuticals, and consumer health products.
Novartis is the only company with leading positions in these areas.
In 2008, the Group's continuing operations achieved net sales of USD
41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2
billion was invested in R&D activities throughout the Group.
Headquartered in Basel, Switzerland, Novartis Group companies employ
approximately 96,700 full-time-equivalent associates and operate in
more than 140 countries around the world. For more information,
please visit http://www.novartis.com.

# # #

Novartis Media Relations


Central media line : +41 61 324 2200
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com


e-mail: media.relations@novartis.com

Novartis Investor Relations

Central phone: +41 61 324
7944
Ruth Metzler-Arnold +41 61 324 North America:
9980
Pierre-Michel Bringer +41 61 324 Richard Jarvis +1 212 830
1065 2433
John Gilardi +41 61 324 Jill Pozarek +1 212 830
3018 2445
Thomas +41 61 324 Edwin Valeriano +1 212 830
Hungerbuehler 8425 2456
Isabella Zinck +41 61 324
7188

e-mail: e-mail:
investor.relations@novartis.com investor.relations@novartis.com



--- End of Message ---

Novartis International AG
Posfach Basel

WKN: 904278; ISIN:
CH0012005267; Index: SLCI, SMI, SPI, SLIFE;
Listed: Main Market in SIX Swiss Exchange, ZLS in BX Berne eXchange;
Copyright © Hugin AS 2009. All rights reserved.



 
 ||| Themen-Infos 
· Mehr zu dem Thema Contracts & Corporate events & IPOs &

Der meistgelesene Artikel zu dem Thema Contracts & Corporate events & IPOs &:
Change on the Board of Directors of Feintool Holding AG

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.073 Sekunden